| Field | Row 1 |
|---|---|
| adsh | 0000950170-25-070956 |
| cik | 1865494 |
| name | IO BIOTECH, INC. |
| sic | 2834 |
| countryba | DK |
| stprba | |
| cityba | COPENHAGEN |
| zipba | 2200 |
| bas1 | OLE MAALOES VEH 3 |
| bas2 | |
| baph | 4570702980 |
| countryma | DK |
| stprma | |
| cityma | COPENHAGEN |
| zipma | 2200 |
| mas1 | OLE MAALOES VEH 3 |
| mas2 | |
| countryinc | US |
| stprinc | DE |
| ein | 870909276 |
| former | |
| changed | |
| afs | 4-NON |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250514 |
| accepted | 2025-05-14 08:54:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | iobt-20250331_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0000950170-25-070956 | 20250331 | Accrued Liabilities And Other Liabilities | 12353000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Accrued Liabilities And Other Liabilities | 14108000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Additional Paid In Capital | 413113000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Cash And Cash Equivalents At Carrying Value | 117982000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Cash And Cash Equivalents At Carrying Value | 60031000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Common Stock Value | 66000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Comprehensive Income Net Of Tax | -19263000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Depreciation | 61000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Earnings Per Share Diluted | -0.3400 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | General And Administrative Expense | 2019000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Other Costs; | ||
| 0000950170-25-070956 | 20250331 | Increase Decrease In Accrued Liabilities | -1391000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Increase Decrease In Lease Liability | -191000.0000 | USD | 1 | 0000950170-25-070956 | |||
| 0000950170-25-070956 | 20250331 | Increase Decrease In Other Noncurrent Assets | 807000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Net Income Loss | -22421000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-070956 | 20250331 | Operating Expenses | 22584000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Operating Lease Right Of Use Asset Amortization Expense | 149000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | 194000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-070956 | 20250331 | Preferred Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Research And Development Expense | 6183000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Personnel; | ||
| 0000950170-25-070956 | 20241231 | Accumulated Other Comprehensive Income Loss Net Of Tax | -6851000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Accumulated Other Comprehensive Income Loss Net Of Tax | -6592000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 1569000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 1569000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-070956 | 20240331 | Foreign Currency Transaction Gain Loss Before Tax | -462000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Foreign Currency Transaction Gain Loss Before Tax | -105000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | General And Administrative Expense | 1073000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Professional Services; | ||
| 0000950170-25-070956 | 20250331 | General And Administrative Expense | 1381000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Professional Services; | ||
| 0000950170-25-070956 | 20250331 | Net Cash Provided By Used In Financing Activities | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Nonoperating Income Expense | 309000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Operating Lease Liability Current | 717000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Stockholders Equity | 66000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-070956 | 20241231 | Operating Lease Liability Noncurrent | 1198000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Operating Lease Liability Noncurrent | 1028000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | 194000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Prepaid Expense And Other Assets Current | 4920000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Research And Development Expense | 14311000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Research And Development Expense | 2167000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Chemistry Manufacturing And Control; | ||
| 0000950170-25-070956 | 20240331 | Research And Development Expense | 337000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Preclinical Studies And Activities; | ||
| 0000950170-25-070956 | 20250331 | Research And Development Expense | 16375000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Share Based Compensation | 1567000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20231231 | Stockholders Equity | 133162000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Stockholders Equity | -283279000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-070956 | 20250331 | Additional Paid In Capital | 414682000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 1567000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 1567000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-070956 | 20250331 | Assets Current | 42342000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Cash And Cash Equivalents At Carrying Value | 37086000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0000950170-25-070956 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | Credit Facility= Two Thousand Twenty Four E I B Term Loan Facility; | ||
| 0000950170-25-070956 | 20250331 | Common Stock Shares Issued | 65880914.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Depreciation | 62000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 154000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Foreign Currency Transaction Gain Loss Realized | -462000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | General And Administrative Expense | 3012000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Personnel; | ||
| 0000950170-25-070956 | 20250331 | Increase Decrease In Accounts Payable | 538000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Investment Income Net | 414000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Net Income Loss | -19457000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-070956 | 20241231 | Net Income Loss | -95500000.0000 | USD | 4 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Operating Expenses | 20197000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Operating Income Loss | -20197000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Operating Lease Liability Current | 735000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Operating Lease Right Of Use Asset | 1725000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Preferred Stock Value | USD | 0 | us-gaap/2024 | ||||
| 0000950170-25-070956 | 20250331 | Prepaid Expense And Other Assets Current | 5256000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Research And Development Expense | 7148000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Clinical Trial Related Activities; | ||
| 0000950170-25-070956 | 20250331 | Research And Development Expense | 7691000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Clinical Trial Related Activities; | ||
| 0000950170-25-070956 | 20250331 | Restricted Cash Noncurrent | 268000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20231231 | Stockholders Equity | -9669000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-070956 | 20240331 | Stockholders Equity | 115466000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Stockholders Equity | 408154000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-070956 | 20241231 | Stockholders Equity | -359313000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-070956 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 60299000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -24943000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20211130 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | Class Of Stock= Preferred Class C; | ||
| 0000950170-25-070956 | 20250331 | Common Stock Shares Authorized | 300000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Comprehensive Income Net Of Tax | -22162000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Earnings Per Share Diluted | -0.3000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -22275000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Liabilities And Stockholders Equity | 67699000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Liabilities Noncurrent | 1198000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Other Assets Noncurrent | 117000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Payments To Acquire Property Plant And Equipment | 11000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Profit Loss | -22421000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Research And Development Expense | -135000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Other Costs; | ||
| 0000950170-25-070956 | 20250331 | Research And Development Expense | -203000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Other Costs; | ||
| 0000950170-25-070956 | 20250331 | Restricted Cash | 268000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Restricted Cash Noncurrent | 268000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Stockholders Equity | 26422000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Stockholders Equity | 414682000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-070956 | 20240331 | Weighted Average Number Of Diluted Shares Outstanding | 65880914.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Weighted Average Number Of Shares Outstanding Basic | 65880914.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Increase Decrease In Accounts Payable | -38000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20211130 | Common Stock Par Or Stated Value Per Share | 0.1600 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0000950170-25-070956 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 118250000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Increase Decrease In Accrued Liabilities | -4647000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Increase Decrease In Lease Liability | -155000.0000 | USD | 1 | 0000950170-25-070956 | |||
| 0000950170-25-070956 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 37354000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -23099000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | 2083000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Net Cash Provided By Used In Operating Activities | -23071000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Other Assets Noncurrent | 924000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Assets Noncurrent | 3394000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20211130 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | Class Of Stock= Preferred Class B; | ||
| 0000950170-25-070956 | 20230731 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | Subsidiary Sale Of Stock= Private Placement; | ||
| 0000950170-25-070956 | 20241231 | Common Stock Shares Outstanding | 65880914.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Earnings Per Share Basic | -0.3400 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | -268000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Foreign Currency Transaction Gain Loss Realized | -105000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | General And Administrative Expense | 6209000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -19042000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Income Tax Expense Benefit | 415000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | 194000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Preferred Stock Shares Authorized | 5000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Retained Earnings Accumulated Deficit | -359313000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Share Based Compensation | 1569000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Stockholders Equity | 47015000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Stockholders Equity | 413113000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-070956 | 20241231 | Stockholders Equity | 66000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-070956 | 20241231 | Assets | 67699000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 143461000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20211031 | Common Stock Shares Authorized | 300000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Common Stock Shares Authorized | 300000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | General And Administrative Expense | 1816000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Other Costs; | ||
| 0000950170-25-070956 | 20240331 | Investment Income Net | 1617000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Liabilities Current | 19486000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Liabilities Current | 18286000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Net Cash Provided By Used In Operating Activities | -24932000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Operating Lease Right Of Use Asset | 1585000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Profit Loss | -19457000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Research And Development Expense | 4794000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Personnel; | ||
| 0000950170-25-070956 | 20231231 | Shares Outstanding | 65880914.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-070956 | 20241231 | Shares Outstanding | 65880914.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-070956 | 20231231 | Stockholders Equity | -263822000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-070956 | 20240331 | Stockholders Equity | -9475000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-070956 | 20241231 | Stockholders Equity | -6851000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-070956 | 20250331 | Stockholders Equity | -6592000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-070956 | 20241231 | Accounts Payable Current | 4661000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Assets | 45736000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Assets Current | 64951000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Assets Noncurrent | 2748000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20211031 | Common Stock Shares Outstanding | 28815267.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Common Stock Value | 66000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | General And Administrative Expense | 5886000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | General And Administrative Expense | 2794000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Personnel; | ||
| 0000950170-25-070956 | 20250331 | Income Tax Expense Benefit | 146000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Increase Decrease In Other Noncurrent Assets | 792000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Liabilities Noncurrent | 1028000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Net Income Loss | -19457000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Net Income Loss Available To Common Stockholders Basic | -19457000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Nonoperating Income Expense | 1155000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | 259000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Preferred Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Preferred Stock Value | USD | 0 | us-gaap/2024 | ||||
| 0000950170-25-070956 | 20241231 | Property Plant And Equipment Net | 638000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Research And Development Expense | 412000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Preclinical Studies And Activities; | ||
| 0000950170-25-070956 | 20240331 | Restricted Cash | 268000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20231231 | Stockholders Equity | 406587000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-070956 | 20250331 | Weighted Average Number Of Diluted Shares Outstanding | 65880914.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Weighted Average Number Of Shares Outstanding Basic | 65880914.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Accounts Payable Current | 5198000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0000950170-25-070956 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Common Stock Shares Issued | 65880914.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Common Stock Shares Outstanding | 65880914.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Earnings Per Share Basic | -0.3000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | 700000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20241231 | Liabilities | 20684000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Liabilities | 19314000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Liabilities And Stockholders Equity | 45736000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Net Cash Provided By Used In Financing Activities | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Net Cash Provided By Used In Investing Activities | -11000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Net Cash Provided By Used In Investing Activities | -28000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Net Income Loss | -22421000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Net Income Loss Available To Common Stockholders Basic | -22421000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Operating Income Loss | -22584000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Operating Lease Right Of Use Asset Amortization Expense | 166000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | 259000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | 259000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-070956 | 20250331 | Payments To Acquire Property Plant And Equipment | 28000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20211031 | Preferred Stock Shares Authorized | 5000000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Undesignated Preferred Stock; | ||
| 0000950170-25-070956 | 20250331 | Preferred Stock Shares Authorized | 5000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Property Plant And Equipment Net | 617000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20250331 | Research And Development Expense | 2292000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Chemistry Manufacturing And Control; | ||
| 0000950170-25-070956 | 20250331 | Retained Earnings Accumulated Deficit | -381734000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-070956 | 20240331 | Shares Outstanding | 65880914.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-070956 | 20250331 | Shares Outstanding | 65880914.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-070956 | 20231231 | Stockholders Equity | 66000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-070956 | 20240331 | Stockholders Equity | 66000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-070956 | 20250331 | Stockholders Equity | -381734000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Increase Decrease In Other Noncurrent Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Other Noncurrent Assets | Amount of increase (decrease) in noncurrent assets classified as other. |
| Operating Lease Liability Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Current | Present value of lessee's discounted obligation for lease payments from operating lease, classified as current. |
| Income Tax Expense Benefit | us-gaap/2024 | 0 | 0 | monetary | D | D | Income Tax Expense (Benefit) | Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. |
| Payments To Acquire Property Plant And Equipment | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Property, Plant, and Equipment | The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. |
| Comprehensive Income Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | C | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. |
| Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Liabilities And Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Retained Earnings Accumulated Deficit | us-gaap/2024 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Additional Paid In Capital | us-gaap/2024 | 0 | 0 | monetary | I | C | Additional Paid in Capital | Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. |
| Common Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Common Stock, Par or Stated Value Per Share | Face amount or stated value per share of common stock. | |
| Common Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | 0 | 0 | monetary | D | D | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Net Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Accrued Liabilities And Other Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Accrued Liabilities and Other Liabilities | Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. |
| Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | I | C | Accumulated Other Comprehensive Income (Loss), Net of Tax | Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. |
| Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Common Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Earnings Per Share Diluted | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Operating Lease Right Of Use Asset | us-gaap/2024 | 0 | 0 | monetary | I | D | Operating Lease, Right-of-Use Asset | Amount of lessee's right to use underlying asset under operating lease. |
| Other Assets Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Other Assets, Noncurrent | Amount of noncurrent assets classified as other. |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax | Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | 0 | 0 | monetary | D | C | APIC, Share-Based Payment Arrangement, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. |
| Preferred Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Issued | Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. | |
| Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. |
| Foreign Currency Transaction Gain Loss Before Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Gain (Loss), Foreign Currency Transaction, before Tax | Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Prepaid Expense and Other Assets | Amount of increase (decrease) in prepaid expenses, and assets classified as other. |
| Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Nonoperating Income (Expense) | The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). |
| Preferred Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Preferred Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Profit Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. |
| Liabilities Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Noncurrent | Amount of obligation due after one year or beyond the normal operating cycle, if longer. |
| Net Cash Provided By Used In Operating Activities | us-gaap/2024 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Operating Expenses | us-gaap/2024 | 0 | 0 | monetary | D | D | Operating Expenses | Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. |
| Operating Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Prepaid Expense And Other Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Prepaid Expense and Other Assets, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| Restricted Cash | us-gaap/2024 | 0 | 0 | monetary | I | D | Restricted Cash | Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. |
| Restricted Cash Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Restricted Cash, Noncurrent | Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | us-gaap/2024 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect | Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Common Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| General And Administrative Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | General and Administrative Expense | The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. |
| Research And Development Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Research and Development Expense | Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Accounts Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Assets Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Noncurrent | Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. |
| Commitments And Contingencies | us-gaap/2024 | 0 | 0 | monetary | I | C | Commitments and Contingencies | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Common Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Increase Decrease In Accounts Payable | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable | The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. |
| Investment Income Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Investment Income, Net | Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Net Income Loss Available To Common Stockholders Basic | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Available to Common Stockholders, Basic | Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. |
| Operating Lease Right Of Use Asset Amortization Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Operating Lease, Right-of-Use Asset, Periodic Reduction | Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. |
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent | Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. |
| Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Preferred Stock, Par or Stated Value Per Share | Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. | |
| Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Shares, Outstanding | Number of shares issued which are neither cancelled nor held in the treasury. | |
| Increase Decrease In Lease Liability | 0000950170-25-070956 | 1 | 0 | monetary | D | D | Increase (Decrease) In Lease Liability | Increase (decrease) in lease liability |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Depreciation | us-gaap/2024 | 0 | 0 | monetary | D | D | Depreciation | The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. |
| Earnings Per Share Basic | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Net Cash Provided By Used In Investing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Preferred Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Authorized | The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. | |
| Preferred Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Outstanding | Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. | |
| Foreign Currency Transaction Gain Loss Realized | us-gaap/2024 | 0 | 0 | monetary | D | C | Realized Gain (Loss), Foreign Currency Transaction, before Tax | Amount, before tax, of realized gain (loss) from foreign currency transaction. |
| Increase Decrease In Accrued Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accrued Liabilities | The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. |
| Operating Lease Liability Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Noncurrent | Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. |
| Property Plant And Equipment Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Property, Plant and Equipment, Net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0000950170-25-070956 | 2 | 5 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0000950170-25-070956 | 2 | 6 | BS | 0 | H | Prepaid Expense And Other Assets Current | us-gaap/2024 | Prepaid expenses and other current assets | 0 |
| 0000950170-25-070956 | 2 | 7 | BS | 0 | H | Assets Current | us-gaap/2024 | Total current assets | 0 |
| 0000950170-25-070956 | 2 | 8 | BS | 0 | H | Restricted Cash Noncurrent | us-gaap/2024 | Restricted cash | 0 |
| 0000950170-25-070956 | 2 | 9 | BS | 0 | H | Property Plant And Equipment Net | us-gaap/2024 | Property and equipment, net | 0 |
| 0000950170-25-070956 | 2 | 10 | BS | 0 | H | Operating Lease Right Of Use Asset | us-gaap/2024 | Right of use lease asset | 0 |
| 0000950170-25-070956 | 2 | 11 | BS | 0 | H | Other Assets Noncurrent | us-gaap/2024 | Other non-current assets | 0 |
| 0000950170-25-070956 | 2 | 12 | BS | 0 | H | Assets Noncurrent | us-gaap/2024 | Total non-current assets | 0 |
| 0000950170-25-070956 | 2 | 13 | BS | 0 | H | Assets | us-gaap/2024 | Total assets | 0 |
| 0000950170-25-070956 | 2 | 16 | BS | 0 | H | Accounts Payable Current | us-gaap/2024 | Accounts payable | 0 |
| 0000950170-25-070956 | 2 | 17 | BS | 0 | H | Operating Lease Liability Current | us-gaap/2024 | Lease liability - current | 0 |
| 0000950170-25-070956 | 2 | 18 | BS | 0 | H | Accrued Liabilities And Other Liabilities | us-gaap/2024 | Accrued expenses and other current liabilities | 0 |
| 0000950170-25-070956 | 2 | 19 | BS | 0 | H | Liabilities Current | us-gaap/2024 | Total current liabilities | 0 |
| 0000950170-25-070956 | 2 | 20 | BS | 0 | H | Operating Lease Liability Noncurrent | us-gaap/2024 | Lease liability - noncurrent | 0 |
| 0000950170-25-070956 | 2 | 21 | BS | 0 | H | Liabilities Noncurrent | us-gaap/2024 | Total non-current liabilities | 0 |
| 0000950170-25-070956 | 2 | 22 | BS | 0 | H | Liabilities | us-gaap/2024 | Total liabilities | 0 |
| 0000950170-25-070956 | 2 | 23 | BS | 0 | H | Commitments And Contingencies | us-gaap/2024 | Commitments and contingencies (Note 10) | 0 |
| 0000950170-25-070956 | 2 | 25 | BS | 0 | H | Preferred Stock Value | us-gaap/2024 | Preferred stock, par value of $0.001 per share; 5,000,000 shares authorized, no shares issued and outstanding as of March 31, 2025 and December 31, 2024 | 0 |
| 0000950170-25-070956 | 2 | 26 | BS | 0 | H | Common Stock Value | us-gaap/2024 | Common stock, par value of $0.001 per share; 300,000,000 shares authorized at March 31, 2025 and December 31, 2024; 65,880,914 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 0 |
| 0000950170-25-070956 | 2 | 27 | BS | 0 | H | Additional Paid In Capital | us-gaap/2024 | Additional paid-in capital | 0 |
| 0000950170-25-070956 | 2 | 28 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Accumulated deficit | 0 |
| 0000950170-25-070956 | 2 | 29 | BS | 0 | H | Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | Accumulated other comprehensive loss | 0 |
| 0000950170-25-070956 | 2 | 30 | BS | 0 | H | Stockholders Equity | us-gaap/2024 | Total stockholders' equity | 0 |
| 0000950170-25-070956 | 2 | 31 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2024 | Total liabilities and stockholders' equity | 0 |
| 0000950170-25-070956 | 3 | 3 | BS | 1 | H | Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | Preferred stock, par value | 0 |
| 0000950170-25-070956 | 3 | 4 | BS | 1 | H | Preferred Stock Shares Authorized | us-gaap/2024 | Preferred stock, shares authorized | 0 |
| 0000950170-25-070956 | 3 | 5 | BS | 1 | H | Preferred Stock Shares Issued | us-gaap/2024 | Preferred stock, shares issued | 0 |
| 0000950170-25-070956 | 3 | 6 | BS | 1 | H | Preferred Stock Shares Outstanding | us-gaap/2024 | Preferred stock, shares outstanding | 0 |
| 0000950170-25-070956 | 3 | 7 | BS | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2024 | Common stock, par value | 0 |
| 0000950170-25-070956 | 3 | 8 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2024 | Common stock, shares authorized | 0 |
| 0000950170-25-070956 | 3 | 9 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2024 | Common stock, shares issued | 0 |
| 0000950170-25-070956 | 3 | 10 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2024 | Common stock, shares outstanding | 0 |
| 0000950170-25-070956 | 4 | 2 | IS | 0 | H | Research And Development Expense | us-gaap/2024 | Research and development | 0 |
| 0000950170-25-070956 | 4 | 3 | IS | 0 | H | General And Administrative Expense | us-gaap/2024 | General and administrative | 0 |
| 0000950170-25-070956 | 4 | 4 | IS | 0 | H | Operating Expenses | us-gaap/2024 | Total operating expenses | 0 |
| 0000950170-25-070956 | 4 | 5 | IS | 0 | H | Operating Income Loss | us-gaap/2024 | Loss from operations | 0 |
| 0000950170-25-070956 | 4 | 7 | IS | 0 | H | Foreign Currency Transaction Gain Loss Before Tax | us-gaap/2024 | Currency exchange loss, net | 0 |
| 0000950170-25-070956 | 4 | 8 | IS | 0 | H | Investment Income Net | us-gaap/2024 | Interest income | 0 |
| 0000950170-25-070956 | 4 | 9 | IS | 0 | H | Nonoperating Income Expense | us-gaap/2024 | Total other income (expense), net | 0 |
| 0000950170-25-070956 | 4 | 10 | IS | 0 | H | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | Loss before income tax expense | 0 |
| 0000950170-25-070956 | 4 | 11 | IS | 0 | H | Income Tax Expense Benefit | us-gaap/2024 | Income taxes expense | 0 |
| 0000950170-25-070956 | 4 | 12 | IS | 0 | H | Net Income Loss | us-gaap/2024 | Net loss | 0 |
| 0000950170-25-070956 | 4 | 13 | IS | 0 | H | Net Income Loss Available To Common Stockholders Basic | us-gaap/2024 | Net loss attributable to common shareholders | 0 |
| 0000950170-25-070956 | 4 | 14 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2024 | Net loss per common share, basic | 0 |
| 0000950170-25-070956 | 4 | 15 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2024 | Net loss per common share, diluted | 0 |
| 0000950170-25-070956 | 4 | 16 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | Weighted-average number of shares used in computing net loss per common share, basic | 0 |
| 0000950170-25-070956 | 4 | 17 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | Weighted-average number of shares used in computing net loss per common share, diluted | 0 |
| 0000950170-25-070956 | 4 | 19 | IS | 0 | H | Net Income Loss | us-gaap/2024 | Net Income (Loss) | 0 |
| 0000950170-25-070956 | 4 | 20 | IS | 0 | H | Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | us-gaap/2024 | Foreign currency translation | 0 |
| 0000950170-25-070956 | 4 | 21 | IS | 0 | H | Comprehensive Income Net Of Tax | us-gaap/2024 | Total comprehensive loss | 0 |
| 0000950170-25-070956 | 5 | 9 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Balance | 0 |
| 0000950170-25-070956 | 5 | 10 | EQ | 0 | H | Shares Outstanding | us-gaap/2024 | Balance, shares | 0 |
| 0000950170-25-070956 | 5 | 11 | EQ | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | Equity-based compensation | 0 |
| 0000950170-25-070956 | 5 | 12 | EQ | 0 | H | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | us-gaap/2024 | Foreign currency translation | 0 |
| 0000950170-25-070956 | 5 | 13 | EQ | 0 | H | Net Income Loss | us-gaap/2024 | Net Income (Loss) | 0 |
| 0000950170-25-070956 | 5 | 14 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Balance | 0 |
| 0000950170-25-070956 | 5 | 15 | EQ | 0 | H | Shares Outstanding | us-gaap/2024 | Balance, shares | 0 |
| 0000950170-25-070956 | 6 | 2 | CF | 0 | H | Profit Loss | us-gaap/2024 | Net loss | 0 |
| 0000950170-25-070956 | 6 | 4 | CF | 0 | H | Depreciation | us-gaap/2024 | Depreciation | 0 |
| 0000950170-25-070956 | 6 | 5 | CF | 0 | H | Share Based Compensation | us-gaap/2024 | Equity-based compensation | 0 |
| 0000950170-25-070956 | 6 | 6 | CF | 0 | H | Operating Lease Right Of Use Asset Amortization Expense | us-gaap/2024 | Amortization of right of use lease asset | 0 |
| 0000950170-25-070956 | 6 | 7 | CF | 0 | H | Foreign Currency Transaction Gain Loss Realized | us-gaap/2024 | Foreign currency loss | 1 |
| 0000950170-25-070956 | 6 | 9 | CF | 0 | H | Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | Prepaid expenses and other current assets | 1 |
| 0000950170-25-070956 | 6 | 10 | CF | 0 | H | Increase Decrease In Other Noncurrent Assets | us-gaap/2024 | Other non-current assets | 1 |
| 0000950170-25-070956 | 6 | 11 | CF | 0 | H | Increase Decrease In Accounts Payable | us-gaap/2024 | Accounts payable | 0 |
| 0000950170-25-070956 | 6 | 12 | CF | 0 | H | Increase Decrease In Lease Liability | 0000950170-25-070956 | Lease liability | 0 |
| 0000950170-25-070956 | 6 | 13 | CF | 0 | H | Increase Decrease In Accrued Liabilities | us-gaap/2024 | Accrued expenses and other current liabilities | 0 |
| 0000950170-25-070956 | 6 | 14 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2024 | Net cash used in operating activities | 0 |
| 0000950170-25-070956 | 6 | 16 | CF | 0 | H | Payments To Acquire Property Plant And Equipment | us-gaap/2024 | Purchase of property and equipment | 1 |
| 0000950170-25-070956 | 6 | 17 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2024 | Net cash used in investing activities | 0 |
| 0000950170-25-070956 | 6 | 19 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2024 | Net cash provided by financing activities | 0 |
| 0000950170-25-070956 | 6 | 20 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | us-gaap/2024 | Net decrease in cash, cash equivalents and restricted cash | 0 |
| 0000950170-25-070956 | 6 | 21 | CF | 0 | H | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | Effect of exchange rate changes on cash, cash equivalents and restricted cash | 0 |
| 0000950170-25-070956 | 6 | 22 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | Cash, cash equivalents and restricted cash, beginning of period | 0 |
| 0000950170-25-070956 | 6 | 23 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | Cash, cash equivalents and restricted cash, end of period | 0 |
| 0000950170-25-070956 | 6 | 25 | CF | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0000950170-25-070956 | 6 | 26 | CF | 0 | H | Restricted Cash | us-gaap/2024 | Restricted cash | 0 |
| 0000950170-25-070956 | 6 | 27 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | Total cash, cash equivalents and restricted cash | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |